Prostvac In Combination With Yervoy Yields A Survival Advantage

There is some really exciting news on the horizon around immunotherapy for advanced prostate cancer. Bavarian Nordic, the pharmaseutical company that has, along with the National Cancer Institute (NCI), been running clinical trials on Prostvac has unoffically let it been known that Prostvac when combined with another investigational immunologic therapy, Yervoy, has helped to significantly [...]

Malecare Adds A New Teleconference About Immunotherapy and Advanced Prostate Cancer

Malecare announces the addition of our latest and informative teleconference about Immunotherapy and Advanced Prostate Cancer.  Joining me in the conference is Dr. Nicholas J. Vogelzang, M.D., a medical oncologist with the Comprehensive Cancer Centers of Nevada (CCCN) and serves as chair and site research leader, and as medical director of the Developmental Therapeutics Committee and Member [...]

A Correction of A Prior Post – How About Entering the Prostvac-VF Trail and Then Have Provenge?

On March 4th I wrote a post which included a suggestion that combining Provenge and the clinical trial of Prostvac-VF might provide an interesting one-two punch against advanced prostate cancer.  In the post I suggested that it could be interesting to have Provenge and then move immediately on to Prostvac. This was an error, I [...]

Castrate Resistant Prostate Cancer- What To Do Next?

Confusion, confusion and more confusion, that is how I would describe the current decision making process for a man with prostate cancer that has become newly castrate resistant. Just a few years ago the decision tree was clear, castrate resistant, immediately on to chemotherapy with docetaxel. Today, in this treatment space, we have a number [...]

Immune Therapy & A Rising PSA Coupled With Disease Progression – Does It Work?

Why does PSA continue to rise and prostate cancer disease continue to progress (new tumors develop and existing tumors continue to get bigger) when a man has an immune system treatment to go after their prostate cancer? This issue is probably the major marketing hurdle faced by Dendreon’s Provenge and based on the current statistics [...]

Go to Top